The study is of double-blind; parallel groups dose escalation design. In each cohort of 39 participants 30 will receive Gamma-PN3; 3 will receive Prevenar; 3 will receive Pneumovax and 3 saline placebo.~The doses of Gamma-PN3 will be 50mcg; 250 mcg and 1000 mcg of protein content.
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.